



Letter to the Editor

## Going One Up with Paper-based Chemiluminescent Assay Technology

Syed Imran Ali Shah, MBBS, MPhil, DIC, CHPE, PhD<sup>1</sup> 

<sup>1</sup>Department of Biochemistry, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.



**\*Corresponding author:**

Syed Imran Ali Shah,  
Department of Biochemistry,  
CMH Lahore Medical College  
and Institute of Dentistry,  
Lahore, Pakistan.

s.shah10@alumni.imperial.  
ac.uk

Received : 16 March 2023

Accepted : 25 April 2023

Published : 10 June 2023

**DOI**

10.25259/GJMPBU\_28\_2023

**Quick Response Code:**



Dear Sir,

We have read with interest the article by Khan *et al.* (Global Journal of Medical, Pharmaceutical, and Biochemical Update, Volume 18,<sup>[1]</sup> Year 2023) comparing and contrasting enzyme-linked immunosorbent assay (ELISA) and chemiluminescent immunoassay (CLIA) techniques.<sup>[1]</sup> As inferred by the authors, it is indeed true that CLIA offers a better detection range than ELISA. Considering this detection superiority of CLIA, it is pertinent to highlight that in recent times, a combination of CLIA detection and paper-based technology has surfaced as a promising solution for creating advanced analytical devices for point-of-care (POC) applications.<sup>[2]</sup> Paper-based CLIA is a diagnostic tool that uses a paper substrate to detect disease markers through chemiluminescence reactions. This approach allows for high selectivity and specificity while maintaining the simplicity of the instrumentation necessary for measuring the light signal. This technology can detect disease markers at low concentrations, making it a valuable tool for the early detection and monitoring of diseases such as cancer, infectious diseases, allergic disorders, and autoimmune disorders. The specificity of the technology allows for accurate diagnosis and differentiation of diseases with similar symptoms. Moreover, paper-based CLIA offers the advantages of portability, versatility, ease of use, compactness, and low cost.<sup>[3]</sup> The paper substrate is inexpensive, widely available, and biodegradable, making it an accessible option for healthcare settings with limited resources. In addition, the technology requires only a small amount of samples, reducing the cost and invasiveness of the diagnostic process.<sup>[4]</sup>

However, the limited stability of bioreagents and the need to add reagents manually during the analytical protocol have hindered the commercialization of paper-based CLIA. The paper substrate may also be susceptible to interference from other substances in the sample, thus potentially reducing accuracy. Paper-based CLIA has limited multiplexing capabilities, and at present, the technology is only able to detect a single disease marker at a time, which can be time-consuming and impractical for monitoring multiple diseases or disease progression over time. This limitation may be particularly relevant for diseases with multiple biomarkers or for monitoring response to treatment.<sup>[5,6]</sup> Researchers are continuously improving paper-based CLIA to meet the ideal POC requirements for successful market implementation. With optical signal measurement using smartphones,<sup>[7]</sup> paper-based CLIA may find widespread use as a bioanalytic tool.

### Declaration of patient consent

Patient's consent not required as there are no patients in this study.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©2023 Published by Scientific Scholar on behalf of Global Journal of Medical, Pharmaceutical, and Biomedical Update

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

1. Khan M, Shah SH, Salman M, Abdullah M, Hayat F, Akbar S. Enzyme-linked immunosorbent assay versus chemiluminescent immunoassay: A general overview. *Glob J Med Pharm Biomed Update* 2023;18:1.
2. Calabretta MM, Zangheri M, Calabria D, Lopreside A, Montali L, Marchegiani E, *et al.* Paper-based immunosensors with bio-chemiluminescence detection. *Sensors (Basel)* 2021;21:4309.
3. Han X, Cao M, Wu M, Wang YJ, Yu C, Zhang C, *et al.* A paper-based chemiluminescence immunoassay device for rapid and high-throughput detection of allergen-specific IgE. *Analyst* 2019;144:2584-93.
4. Anand U, Chandel AK, Oleksak P, Mishra A, Krejcar O, Raval IH, *et al.* Recent advances in the potential applications of luminescence-based, SPR-based, and carbon-based biosensors. *Appl Microbiol Biotechnol* 2022;106:2827-53.
5. Bendicho C, Lavilla I, Pena-Pereira F, de la Calle I, Romero V. Nanomaterial-integrated cellulose platforms for optical sensing of trace metals and anionic species in the environment. *Sensors (Basel)* 2021;21:604.
6. Alahmad W, Varanusupakul P, Kaneta T. Chemiluminescence paper-based analytical devices. In: de Araujo WR, Paixão TR, editors. *Paper-Based Analytical Devices for Chemical Analysis and Diagnostics*. Ch. 7. Netherlands: Elsevier; 2022. p. 169-82.
7. Calabria D, Zangheri M, Trozzi I, Lazzarini E, Pace A, Mirasoli M, *et al.* Smartphone-based chemiluminescent origami  $\mu$ PAD for the rapid assessment of glucose blood levels. *Biosensors (Basel)* 2021;11:381.

**How to cite this article:** Shah SIA. Going one up with paper-based chemiluminescent assay technology. *Glob J Med Pharm Biomed Update* 2023;18:10.